BioVie Inc. Research and Development Expense
BioVie Inc. (BIVI) reported Research and Development Expense of $13.96 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- BioVie Inc. research and development expense for the quarter ending 2026-06-30 was $3.58M, a 192.36% increase year-over-year.
- BioVie Inc. research and development expense for the quarter ending 2026-03-31 was $3.18M, a 136.21% increase year-over-year.
- BioVie Inc. research and development expense for the quarter ending 2025-12-31 was $4.27M, a 9.25% decline year-over-year.
- BioVie Inc. research and development expense for the quarter ending 2025-09-30 was $2.94M, a 47.54% increase year-over-year.
- BioVie Inc. research and development expense for fiscal 2026 was $13.96M, a 50.67% increase from fiscal 2025.
- BioVie Inc. research and development expense for fiscal 2025 was $9.27M.
- BioVie Inc. research and development expense for fiscal 2023 was $33.30M, a 92.95% increase from fiscal 2022.
- BioVie Inc. research and development expense for fiscal 2022 was $17.26M, a 578.22% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.58M derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | $6.76M derived: sum of 2 quarters · filed 2026-08-13 | $11.03M derived: sum of 3 quarters · filed 2026-08-13 | $13.96M 10-K · filed 2026-08-13 | ||||
| 2026-03-31 | $3.18M S-1/A · filed 2026-08-06 | $7.45M derived: sum of 2 quarters · filed 2026-08-06 | $10.38M S-1/A · filed 2026-08-06 | $11.61M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $4.27M 10-Q · filed 2026-02-06 | $7.21M 10-Q · filed 2026-02-06 | $8.43M derived: sum of 3 quarters · filed 2026-08-13 | $9.78M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-09-30 | $2.94M 10-Q · filed 2025-11-10 | $4.16M derived: sum of 2 quarters · filed 2026-08-13 | $5.51M derived: sum of 3 quarters · filed 2026-08-13 | $10.21M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.22M derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | $2.57M derived: sum of 2 quarters · filed 2026-08-13 | $7.27M derived: sum of 3 quarters · filed 2026-08-13 | $9.27M 10-K · filed 2026-08-13 | ||||
| 2025-03-31 | $1.34M S-1/A · filed 2026-08-06 | $6.05M derived: sum of 2 quarters · filed 2026-08-06 | $8.04M S-1/A · filed 2026-08-06 | $10.09M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-12-31 | $4.70M 10-Q · filed 2026-02-06 | $6.70M 10-Q · filed 2026-02-06 | $8.75M derived: sum of 3 quarters · filed 2026-08-06 | $14.45M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-09-30 | $1.99M 10-Q · filed 2025-11-10 | $4.04M derived: sum of 2 quarters · filed 2026-08-06 | $9.74M derived: sum of 3 quarters · filed 2026-08-06 | $16.21M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-06-30 | $2.05M derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | $7.75M derived: sum of 2 quarters · filed 2026-08-06 | $14.22M derived: sum of 3 quarters · filed 2026-08-06 | $23.10M S-1/A · filed 2026-08-06 | ||||
| 2024-03-31 | $5.70M 10-Q · filed 2025-05-12 | $12.17M derived: sum of 2 quarters · filed 2025-05-12 | $21.05M 10-Q · filed 2025-05-12 | $29.35M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $6.47M 10-Q · filed 2025-02-11 | $15.35M 10-Q · filed 2025-02-11 | $23.65M derived: sum of 3 quarters · filed 2025-02-11 | $34.84M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-09-30 | $8.88M 10-Q · filed 2024-11-13 | $17.18M derived: sum of 2 quarters · filed 2024-11-13 | $28.37M derived: sum of 3 quarters · filed 2024-11-13 | $35.41M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $19.50M derived: sum of 2 quarters · filed 2024-09-30 | $26.53M derived: sum of 3 quarters · filed 2024-09-30 | $33.30M 10-K · filed 2024-09-30 | ||||
| 2023-03-31 | $11.20M 10-Q · filed 2024-05-14 | $18.23M derived: sum of 2 quarters · filed 2024-05-14 | $25.00M 10-Q · filed 2024-05-14 | $30.87M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $7.03M 10-Q · filed 2024-02-13 | $13.80M 10-Q · filed 2024-02-13 | $19.68M derived: sum of 3 quarters · filed 2024-02-13 | $23.25M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | $6.77M 10-Q · filed 2023-11-08 | $12.64M derived: sum of 2 quarters · filed 2023-11-08 | $16.22M derived: sum of 3 quarters · filed 2023-11-08 | $20.93M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-16 | $9.45M derived: sum of 2 quarters · filed 2023-08-16 | $14.16M derived: sum of 3 quarters · filed 2023-08-16 | $17.26M 10-K · filed 2023-08-16 | ||||
| 2022-03-31 | $3.58M 10-Q · filed 2023-05-12 | $8.29M derived: sum of 2 quarters · filed 2023-05-12 | $11.39M 10-Q · filed 2023-05-12 | $11.91M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $4.71M 10-Q · filed 2023-02-10 | $4.59M 10-Q · filed 2022-02-08 | $7.81M 10-Q · filed 2023-02-10 | $7.44M 10-Q · filed 2022-02-08 | $8.33M derived: sum of 3 quarters · filed 2023-02-10 | $9.12M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-09-30 | $3.09M 10-Q · filed 2022-11-04 | $2.85M 10-Q · filed 2021-11-10 | $3.62M derived: sum of 2 quarters · filed 2022-11-04 | $4.41M derived: sum of 3 quarters · filed 2022-11-04 | $5.35M derived: sum of 4 quarters · filed 2022-11-04 | |||
| 2021-06-30 | $525.09K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $1.31M derived: sum of 2 quarters · filed 2022-09-27 | $2.25M derived: sum of 3 quarters · filed 2022-09-27 | $2.54M 10-K · filed 2022-09-27 | $133.19M 10-K · filed 2021-08-30 | |||
| 2021-03-31 | $789.58K 10-Q · filed 2022-05-11 | $696.66K 10-Q · filed 2021-05-10 | $1.73M derived: sum of 2 quarters · filed 2022-05-11 | $2.02M 10-Q · filed 2022-05-11 | $1.76M 10-Q · filed 2021-05-10 | $1.98M derived: sum of 4 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $938.10K 10-Q · filed 2022-02-08 | $1.06M 10-Q · filed 2022-02-08 | $1.19M derived: sum of 3 quarters · filed 2022-02-08 | $1.54M derived: sum of 4 quarters · filed 2022-02-08 | ||||
| 2020-09-30 | $100.91K 10-Q · filed 2021-11-10 | $248.37K derived: sum of 2 quarters · filed 2021-11-10 | $601.57K derived: sum of 3 quarters · filed 2021-11-10 | $948.08K derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $147.46K derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-30 | $500.65K derived: sum of 2 quarters · filed 2021-08-30 | $847.17K derived: sum of 3 quarters · filed 2021-08-30 | $1.15M 10-K · filed 2021-08-30 | ||||
| 2020-03-31 | $353.20K 10-Q · filed 2021-05-10 | $699.71K derived: sum of 2 quarters · filed 2021-05-10 | $1.00M 10-Q · filed 2021-05-10 | $1.32M derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $346.51K 10-Q · filed 2021-01-29 | $688.01K 10-Q · filed 2021-01-29 | $963.74K derived: sum of 3 quarters · filed 2021-01-29 | $1.30M derived: sum of 4 quarters · filed 2021-01-29 | ||||
| 2019-09-30 | $341.50K 10-Q · filed 2020-11-05 | $617.23K derived: sum of 2 quarters · filed 2020-11-05 | $949.06K derived: sum of 3 quarters · filed 2020-11-05 | $1.16M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $275.73K derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-07 | $607.56K derived: sum of 2 quarters · filed 2020-08-07 | $813.58K derived: sum of 3 quarters · filed 2020-08-07 | $1.01M 10-K/A · filed 2020-08-07 | ||||
| 2019-03-31 | $331.83K 10-Q · filed 2020-05-13 | $537.85K derived: sum of 2 quarters · filed 2020-05-13 | $732.37K 10-Q · filed 2020-05-13 | $828.11K derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | $206.02K 10-Q · filed 2020-02-13 | $400.54K 10-Q · filed 2020-02-13 | $496.28K derived: sum of 3 quarters · filed 2020-02-13 | $542.70K derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-09-30 | $194.52K 10-Q · filed 2019-11-19 | $290.26K derived: sum of 2 quarters · filed 2019-11-19 | $336.68K derived: sum of 3 quarters · filed 2019-11-19 | $523.52K derived: sum of 4 quarters · filed 2019-11-19 | ||||
| 2018-06-30 | $95.74K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-27 | $142.16K derived: sum of 2 quarters · filed 2019-09-27 | $329.00K derived: sum of 3 quarters · filed 2019-09-27 | $370.85K 10-K · filed 2019-09-27 | $370.85K 10-K · filed 2018-10-05 | |||
| 2018-03-31 | $46.42K 10-Q · filed 2019-05-10 | $233.26K derived: sum of 2 quarters · filed 2019-05-10 | $275.12K 10-Q · filed 2019-05-10 | $365.60K derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | $186.84K 10-Q · filed 2019-02-12 | $228.69K 10-Q · filed 2019-02-12 | $319.18K derived: sum of 3 quarters · filed 2019-02-12 | $439.22K derived: sum of 4 quarters · filed 2019-02-12 | ||||
| 2017-09-30 | $41.85K 10-Q · filed 2018-11-14 | $132.34K derived: sum of 2 quarters · filed 2018-11-14 | $252.38K derived: sum of 3 quarters · filed 2018-11-14 | $380.94K derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-06-30 | $90.48K derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-05 | $210.53K derived: sum of 2 quarters · filed 2018-10-05 | $339.08K derived: sum of 3 quarters · filed 2018-10-05 | $466.35K 10-K · filed 2018-10-05 | ||||
| 2017-03-31 | $120.04K 10-Q · filed 2018-05-14 | $248.60K derived: sum of 2 quarters · filed 2018-05-14 | $375.87K 10-Q · filed 2018-05-14 | |||||
| 2016-12-31 | $128.56K 10-Q · filed 2018-02-14 | $255.83K 10-Q · filed 2018-02-14 | ||||||
| 2016-09-30 | $127.27K 10-Q · filed 2017-11-08 | |||||||
| 2016-06-30 | $37.90K 10-K · filed 2017-08-24 | |||||||
| 2015-09-30 | $0.00 10-Q/A · filed 2017-01-19 | $796.00 derived: sum of 2 quarters · filed 2017-01-19 | $796.00 derived: sum of 3 quarters · filed 2017-01-19 | $796.00 derived: sum of 4 quarters · filed 2017-01-19 | ||||
| 2015-06-30 | $796.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-28 | $796.00 derived: sum of 2 quarters · filed 2016-09-28 | $796.00 derived: sum of 3 quarters · filed 2016-09-28 | $4.20K 10-K · filed 2016-09-28 | ||||
| 2015-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-23 | $0.00 derived: sum of 2 quarters · filed 2016-05-23 | $3.40K 10-Q · filed 2016-05-23 | $3.40K derived: sum of 4 quarters · filed 2016-05-23 | ||||
| 2014-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-16 | $3.40K 10-Q · filed 2016-02-16 | $3.40K derived: sum of 3 quarters · filed 2016-02-16 | $22.81K derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-09-30 | $3.40K 10-Q · filed 2015-11-13 | $3.40K derived: sum of 2 quarters · filed 2015-11-13 | $22.81K derived: sum of 3 quarters · filed 2015-11-13 | $41.96K derived: sum of 4 quarters · filed 2015-11-13 | ||||
| 2014-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-10-01 | $19.41K derived: sum of 2 quarters · filed 2015-10-01 | $38.56K derived: sum of 3 quarters · filed 2015-10-01 | $49.42K 10-K · filed 2015-10-01 | ||||
| 2014-03-31 | $19.41K 10-Q · filed 2015-05-11 | $38.56K derived: sum of 2 quarters · filed 2015-05-11 | $49.42K 10-Q · filed 2015-05-11 | $49.42K 10-Q · filed 2014-05-09 | ||||
| 2013-12-31 | $19.15K 10-Q · filed 2015-02-05 | $30.01K 10-Q · filed 2015-02-05 | $30.01K 10-Q · filed 2014-01-29 | |||||
| 2013-09-30 | $11.42K 10-Q · filed 2014-11-13 | $11.42K 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |